Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

Ingelheim, Germany and Amsterdam, the Netherlands, 23 April 2025 – Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and global license agreement. Jointly the…

Boehringer agrees new partnership to advance first-in-class precision cancer therapies

**Boehringer Ingelheim Partners with Tessellate Bio to […]

Boehringer Ingelheim inks deal with Tessallate Bio - European Biotechnology Magazine

Boehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments. The post Boehringer Ingelheim inks deal with Tessallate Bio appeared first on European Biotechnology Magazine.

Boehringer to expand oncology presence with $572m Tessellate Bio deal - Pharmaceutical Technology

The agreement gives Boehringer access to Tessellate’s novel approach targeting ALT-dependent tumours.

Boehringer and Tessellate partner to tackle tough cancer targets

Boehringer Ingelheim and Tessellate Bio form a €500m partnership to develop precision therapies targeting ALT-positive cancers.

Boehringer taps Dutch biotech for ALT positive cancer pact exceeding $573M in biobucks

Boehringer Ingelheim has inked a research collaboration with Tessellate Bio to develop precision medicines for cancers that maintain telomere length to survive and grow. The Amsterdam-based biotech could get more than €500 million ($573 million) ...